| INTRODUCTION
Congenital hyperinsulinism (HI) is the most frequent and severe cause of persistent hypoglycemia in infants and children. HI is a heterogeneous condition in terms of molecular genetics, clinical presentation, responsiveness to medical treatment, requirement for surgery, and histopathology. Dominant inactivating mutations in HNF1A and HNF4A have long been associated with maturity-onset diabetes of the young (MODY3 and MODY1). 1 Recently, it has been shown that the phenotype in individuals with these mutations is characterized by HI early in life before evolving to diabetes in later life. [2] [3] [4] The pathophysiology for hyperinsulinism in early life followed by subsequent development of β-cell failure is still unclear. 5 Information available in the literature regarding the clinical characteristics in HNF1A-and HNF4A-HI is limited to case reports or small case series with a short duration of follow-up and the prevalence is not known. The reported cases of HI associated with mutations in HNF1A and HNF4A have been diazoxide responsive with resolution of the HI during infancy, but lasting until childhood in some cases.
We hypothesized that mutations in HNF1A and HNF4A are a more common cause of diazoxide-responsive HI than previously appreciated. The objective of this study is to examine the prevalence of HNF1A and HNF4 mutations in a large cohort of children with HI, and to describe their genotype and phenotypes.
| Study design
This is a retrospective descriptive study. Clinical information was obtained by retrospective chart review.
| Subjects
Children with HI who were managed at The Children's Hospital of Philadelphia (CHOP) Hyperinsulinism Center between 1997 and June 2016 were included in the study. This study was approved by the institutional review board. Written informed consent was obtained from parents of probands included in the study.
The diagnosis of HI was based on evidence of increased insulin secretion/actions, including detectable plasma insulin or C-peptide, and/or inappropriately low plasma β-hydroxybutyrate (BOHB) 
| Mutational analysis
Genomic DNA was obtained from peripheral blood (5 PRIME, Gai- 3.1 | Spectrum of mutations detected in HNF1A and HNF4A
As shown in Table 1 and Figure 1 , a total of 10 unique mutations in HNF1A and HNF4A were identified in 12 children. Of these 10 mutations, 7 have been previously reported in the literature: 3 associated with diabetes, 2 associated with HI, and 2 associated with both diabetes and HI. The remaining 3 mutations are novel: 1 nonsense and 2 frameshift changes. Six children inherited the mutation from their fathers (HNF1A = 5, HNF4A = 1), while 4 cases inherited the mutation from their mothers (HNF1A = 2, HNF4A = 2). There was one de novo variant and parent-of-origin could not be confirmed in one child as parental samples were not available.
| Clinical and biochemical phenotype
The clinical characteristics are summarized in Table 2 . There were no statistically significant differences between children with HNF1A-HI and HNF4A-HI, however, children who carried a mutation in HNF4A were more likely to be born large for gestational age (LGA: birth weight > 90th centile for gestational age) than were children with an HNF1A mutation. Six had family history of diabetes mellitus and among the 10 parents who carried a mutation, 5 were previously known to have either diabetes mellitus or gestational diabetes. None of the children had any history of significant perinatal stress.
The age of presentation ranged from day 1 of life to 2. Table 3 .
| Pharmacological treatment with diazoxide
All children were treated with diazoxide. One HNF1A-HI child (subject 1) was only partially responsive as previously reported. 4 This child was a full term, large for gestational age (4167 g) female. She had transient neonatal hypoglycemia that appeared to resolve after day 3 of life. She presented at 2 years of age with a hypoglycemic seizure. A diagnostic fasting study showed an abbreviated fasting tolerance of 10 hours and the diagnosis of HI was made based on an inappropriate glycemic response to glucagon (increase of 56 mg/dL).
Her BOHB was elevated at 3.56 mmol/L during hypoglycemia. She was started on diazoxide 15 mg/kg/day but a repeat fasting study a Both parents were tested by direct Sanger sequencing after the identification of the mutation in the proband (except for patient 12, in whom both parental samples were not available). LGA, large for gestational age (birth weight > 90th centile for gestational age); SGA, small for gestational age (birth weight < 10th centile for gestational age). showed similar impaired fasting tolerance of 12 hours. She remained well with avoidance of prolonged fasting and diazoxide was stopped at 6.8 years of age. Resolution of HI was documented based on a normal fasting tolerance and a negative glycemic response to glucagon.
| Resolution of HI and development of diabetes mellitus
At the time of analysis, the median age of the children in this cohort was 7.0 years (IQR = 2.3-13.5 years). Diazoxide was discontinued in 5 children at a median age of 6.8 years (IQR = 4.0-6.9 years). Six were still on diazoxide at a median age of 2.3 years (IQR = 1.6-2.5 years). One was lost to follow-up soon after initiation of diazoxide.
Three children, now aged 14.9, 19.6 and 24.9 years, were lost to follow-up. For the rest of the children, only 2 reached the age of 10 years or older. Either hemoglobin A1c (HbA1c) or random glucose was used as screening tests for diabetes after age 10 and none of them had developed diabetes mellitus at the time of analysis.
| Development of extra-pancreatic features
In addition to HI, one child in our series with an HNF4A mutation 
| DISCUSSION
HNF1A and HNF4A mutations are well-accepted causes of MODY but whether the phenotype of individuals with HNF1A mutations, as those with HNF4A mutations, involves hyperinsulinism early in life has been controversial. However, multiple reports have now been published supporting this association. 15 Moreover, in one of the published reports the evolution from hyperinsulinism to diabetes was documented in the same individual who was heterozygous for an HNF1A mutation (p.Arg272His) and presented with fetal macrosomia, hypoglycemia in childhood, followed by diabetes at the age of 19 years. 16 Currently, most published data, especially on HNF1A-HI, are limited to case reports or small case series, and the exact prevalence of HNF1A-and HNF4A-HI is unknown. In a recent cohort of HI patients from Czech, HNF1A-HI was found to be the second commonest cause for HI. 17 We herein report our series of HNF1A-and HNF4A- This is consistent with previously reported cases. 3, 18, 19 One of our patients was only partially responsive to diazoxide.
It was previously reported that birth weights in patients with
HNF1A mutations are usually not affected while HNF4A mutations are associated with macrosomia 2 and most published cases of HNF4A-HI were born large LGA. 18, 19 In our series, 60% of our HNF4A patients were not LGA while HNF1A patients had variable birth weights. This probably reflects the fact that birth weight is determined by a complex interplay of multiple genetic and environmental factors. Therefore, a normal birth weight does not exclude the diagnosis and consideration for HNF1A and HNF4A genetic analysis should not be based on birth weight alone.
The diabetic phenotypes in HNF1A and HNF4A MODY have also been reported to be highly heterogeneous, with variable age of onset and symptoms at diagnosis. 20 This has been shown to be partly related to the type and position of the mutations, which determine the affected number and derivation of isoforms with differential expression in different tissues at different developmental stages, and ultimately the clinical phenotype. 21, 22 For example, in HNF1A MODY, missense mutations in the first 6 exons (predicted to affect all 3 isoforms) are associated with younger onset of diabetes. 23 Similarly,
HNF4A mutations affecting exons 9 and 10 (absent from HNF4A3, HNF4A6, and HNF4A9 isoforms) are associated with later onset of diabetes compared to those with mutations in exons 2-8, where all isoforms were affected. 22 Although we were unable to demonstrate a genotype/phenotype correlation for these cases as it relates to the type and position of the mutation, as in MODY, likely due to the relatively small sample size, genotypes could still be one of the factors contributing to the clinical heterogeneity in HNF1A-and HNF4A-HI and should be further evaluated in future studies.
Interestingly, 2 of the children in our series had some evidence of ketones production at times of hypoglycemia, which is atypical in HI. These 2 children presented relatively older at around 2 years of age. The diagnosis of HI was made based on suppressed FFA (<1.7 mmol/L) and inappropriate response to glucagon, which is highly specific for HI 7 (however, specificity may be lower in the neonatal period). This prompted subsequent treatment with diazoxide and molecular analysis. This highlighted the importance of proper fasting study and critical sample in times of hypoglycemia even for children presenting with "ketotic hypoglycemia" at the "typical age."
These 2 patients have null mutations in HNF1A (nonsense mutation) and 4A (frameshift mutation). One of them actually had history of neonatal hypoglycemia, which apparently resolved in few days with no further workup and all of them only presented for further investigations after the neonatal period. Therefore, we postulate that these patients had mild HI since birth that was not recognized until the fasting interval between feedings increased with age. The mechanism underlying the elevation in betahydroxybutyrate in the setting of hyperinsulinism in these children is not known. It is possible that at the stage when these children were evaluated, the hyperinsulinism was resolving, rather than representing a different biochemical phenotype. This gives hint on the evolution of beta-cell abnormality over time on the spectrum from HI to MODY, which might be similar to the observation of age-dependent evolution in HI caused by dominant potassium channel defect, in which patients present with severe HI in the neonatal period, evolving into milder HI, and subsequently insulin deficiency or even diabetes mellitus in early adulthood. 24 In fact, it has been suggested that the phenotypes in HNF4A-HI can be explained partly by a partial reduction in potassium channel subunit Kir6.2 expression, and that it was demonstrated in mice model that Kir6.2 gene is a transcriptional target for HNF4A. 25 Therefore, it is possible that the difference in phenotype in neonates vs adults reflects an age-dependent difference in the mechanisms regulating insulin secretion. However, this should be interpreted with caution, especially in patient 1, in whom other markers for HI were absent. An alternative explanation for this case would be that he had resolved transient neonatal hypoglycemia, followed by ketotic hypoglycemia at the age of 2 years.
The median age at which diazoxide was discontinued in our series was 6.8 years, which is similar to most reported age of transition into a stable normoglycemic phase. 18, 26 None of the children in our series developed diabetes mellitus at the time of analysis. However, this is a young cohort with a median age of 7 years and some of the older patients, unfortunately, were lost to follow-up. Thus, we were unable to demonstrate the dual phenotype of HNF1A and HNF4A from HI to MODY in this cohort. This is not surprising since the reported mean age of diagnosing diabetes is 20 and 25 years in HNF1A and HNF4A, respectively.
2
In addition to the effect on glucose homeostasis, extra-pancreatic features with transient liver dysfunction and renal Fanconi syndrome was observed in one of our patients. These specific extra-pancreatic features were reported to be mutation-specific to the HNF4A:
c.226c > t/p.Arg76Trp mutation and are not observed in other HNF4A mutation carriers. While renal Fanconi's syndrome was reported to be the consistent feature, liver dysfunction was only observed in some cases. 4, 13, 27 The underlying mechanism is still unclear. The fact that this is only observed with this specific mutation suggests this particular residue must be crucial for the hepatic and renal tubular function. 4, 13 Regardless, this well illustrates the wide regulatory network of HNF4A, not limiting to pancreatic β-cells but also liver and kidney. 4 In addition to the relatively small number of cases in this cohort, one of the limitations of this study is the fact that it was retrospective, and hence, some of the clinical information was incomplete and there were some inconsistencies in characterizing the patients. However, inconsistencies in testing were minimal because all the fasting studies and glucagon stimulation test were standardized in our institution during the study period.
Identifying the molecular etiology in patients who might have mutations in HNF1A or HNF4A is beneficial to both the patient and their family. Because mutations in HNF1A and HNF4A are associated with the development of diabetes later in life, molecular diagnosis of HNF1A or HNF4A is important in order to guide appropriate followup and surveillance after the HI has resolved. In addition, identifying asymptomatic parents or other family members who carry mutations enable early diagnosis of diabetes and initiation of treatment with sulfonylureas to avoided complications later in life. HNF1A and HNF4A mutations are inherited in an autosomal dominant fashion, so each child born to a mutation carrier will have a 50% risk of inheriting the mutation and will be at risk for macrosomia and neonatal hypoglycemia, which requires close monitoring and appropriate intervention. Thus, when evaluating cases of hyperinsulinism that are transient and diazoxide responsive, including those with evidence of some ketone production in the critical sample but inappropriate glycemic response to glucagon, clinicians should have a high index of suspicion for this form of hyperinsulinism and carry out mutation analysis for HNF1A and HNF4A when possible.
